Meyer MC - Search Results

1

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Kidd RS, et al. Among authors: meyer mc. Pharmacogenetics. 1999 Feb;9(1):71-80. doi: 10.1097/00008571-199902000-00010. Pharmacogenetics. 1999. PMID: 10208645

2

Biopharmaceutical factors in seizure control and drug toxicity.

Meyer MC, Straughn AB. Meyer MC, et al. Am J Hosp Pharm. 1993 Dec;50(12 Suppl 5):S17-22. Am J Hosp Pharm. 1993. PMID: 8122697 Review.

3

Variability in the bioavailability of phenytoin capsules in males and females.

Meyer MC, Straughn AB, Mhatre RM, Shah VP, Chen ML, Williams RL, Lesko LJ. Meyer MC, et al. Pharm Res. 2001 Mar;18(3):394-7. doi: 10.1023/a:1011075502215. Pharm Res. 2001. PMID: 11442282 Clinical Trial.

4

Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs.

Dalton JT, Meyer MC, Golub AL. Dalton JT, et al. Among authors: meyer mc. Drug Metab Dispos. 1999 Apr;27(4):432-5. Drug Metab Dispos. 1999. PMID: 10232930

5

Gas chromatographic-mass spectrometric analysis of plasma nifedipine.

Patrick KS, Jarvi EJ, Straughn AB, Meyer MC. Patrick KS, et al. Among authors: meyer mc. J Chromatogr. 1989 Oct 27;495:123-30. doi: 10.1016/s0378-4347(00)82615-8. J Chromatogr. 1989. PMID: 2613797

6

Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.

Dalton JT, Yates CR, Yin D, Straughn A, Marcus SL, Golub AL, Meyer MC. Dalton JT, et al. Among authors: meyer mc. J Pharmacol Exp Ther. 2002 May;301(2):507-12. doi: 10.1124/jpet.301.2.507. J Pharmacol Exp Ther. 2002. PMID: 11961050 Clinical Trial.

7

Bioavailability of 11 phenytoin products.

Melikian AP, Straughn AB, Slywka GW, Whyatt PL, Meyer MC. Melikian AP, et al. Among authors: meyer mc. J Pharmacokinet Biopharm. 1977 Apr;5(2):133-46. doi: 10.1007/BF01066217. J Pharmacokinet Biopharm. 1977. PMID: 576878 No abstract available.

8

In vitro and in vivo evaluation of seven 50 mg and 100 mg nitrofurantoin tablets.

Meyer MC, Wood GC, Straughn AB. Meyer MC, et al. Biopharm Drug Dispos. 1989 May-Jun;10(3):321-9. doi: 10.1002/bdd.2510100310. Biopharm Drug Dispos. 1989. PMID: 2720135 Clinical Trial.

9

Lack of in vivo/in vitro correlations for 50 mg and 250 mg primidone tablets.

Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. Meyer MC, et al. Pharm Res. 1998 Jul;15(7):1085-9. doi: 10.1023/a:1011942530288. Pharm Res. 1998. PMID: 9688064 Clinical Trial.

10

Bioequivalence of immediate-release theophylline capsules.

Meyer MC, Jarvi EJ, Straughn AB, Pelsor FR, Williams RL, Shah VP. Meyer MC, et al. Biopharm Drug Dispos. 1999 Dec;20(9):417-9. doi: 10.1002/1099-081x(199912)20:9<417::aid-bdd205>3.0.co;2-w. Biopharm Drug Dispos. 1999. PMID: 10951430 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179 results

Search Page